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Pediatric brain tumors are significant causes of morbidity and
mortality. It has been hypothesized that they derive from self-
renewing multipotent neural stem cells. Here, we tested whether
different pediatric brain tumors, including medulloblastomas and
gliomas, contain cells with properties similar to neural stem cells.
We find that tumor-derived progenitors form neurospheres that
can be passaged at clonal density and are able to self-renew. Under
conditions promoting differentiation, individual cells are multipo-
tent, giving rise to both neurons and glia, in proportions that
reflect the tumor of origin. Unlike normal neural stem cells,
however, tumor-derived progenitors have an unusual capacity to
proliferate and sometimes differentiate into abnormal cells with
multiple differentiation markers. Gene expression analysis reveals
that both whole tumors and tumor-derived neurospheres express
many genes characteristic of neural and other stem cells, including
CD133, Sox2, musashi-1, bmi-1, maternal embryonic leucine zipper
kinase, and phosphoserine phosphatase, with variation from tu-
mor to tumor. After grafting to neonatal rat brains, tumor-derived
neurosphere cells migrate, produce neurons and glia, and continue
to proliferate for more than 4 weeks. The results show that
pediatric brain tumors contain neural stem-like cells with altered
characteristics that may contribute to tumorigenesis. This finding
may have important implications for treatment by means of
specific targeting of stem-like cells within brain tumors.
Primary malignant central nervous system tumors are the mostfrequent form of solid malignancy in children (1). A heter-
ogeneous group of tumors, some of the most common histolog-
ical types are astrocytomas (52%), primitive neuroectodermal
tumors (PNETs), including medulloblastoma (21%), and high-
grade gliomas (19%) (2). Despite advances in therapy, morbidity
and mortality remain high (3).
The cellular origin of pediatric brain tumors (PBTs) is unclear.
One possibility is that they arise by transformation of prolifer-
ating neural stem cells (NSCs) (4–6), cells with the ability to
self-renew and differentiate into neurons and glia (7). There are
several lines of indirect evidence in support of this hypothesis.
First, PBTs often contain multiple cell types, suggestive of an
origin from a cell with multilineage potential (8). Second, many
PBTs appear to arise from the ventricular zone, the location of
NSCs (9–11). Third, both PBTs and NSCs express nestin, an
intermediate filament characteristic of several progenitors (12–
14). Fourth, PBTs often express genes that regulate proliferation
and self-renewal of normal NSCs (15–17) and mutations in genes
that normally regulate neural stem cell proliferation are fre-
quently found in PBTs. Finally, forced expression of oncogenes
in neural stem and progenitors cells in mice produces tumors that
are similar to primary human tumors (6).
If PBTs contain cells with stem cell properties, an important
question is whether these cells also have abnormal properties
that are responsible for the aberrant and persistent growth of the
tumor (18). In models of breast cancer and acute myelogenous
leukemia, ‘‘cancer stem cells’’ have been isolated and repassaged
into experimental animals to form new tumors, providing strong
evidence that these cells are the root cause of the tumor (19, 20).
Such individual cells are capable of self-renewal, proliferation,
and differentiation to create the complex heterogeneous tumor.
It is unknown whether PBTs contain such cancer stem cells, and,
if so, whether such cells are derived from neural stem cells.
In the current study, we asked whether PBTs contained progen-
itor cells with characteristics similar to those of NSCs. We have
isolated and characterized multipotent, self-renewing cells from
tumor samples, here referred to as ‘‘tumor-derived progenitors,’’
which have both similarities to and differences from normal NSCs
(21). Cells derived from PBTs were able to produce proliferating
neurospheres that could be passaged at clonal density and differ-
entiated into cells with defining antigenic characteristics of neurons
and glia. These neurospheres expressed many genes characteristic
of NSC-derived spheres. Furthermore, like normal neurospheres,
tumor-derived spheres migrated and continued to proliferate when
transplanted into neonatal rat brain. Unlike NSCs, however, these
tumor-derived progenitors were more long-lived and often gave rise
to abnormal dual-phenotype cells. Our data suggest that PBTs arise
from cells with many of the characteristics of NSCs but with
abnormal ability to propagate and differentiate. These studies also
raise the possibility that some tumor-derived cells may be cancer
stem cells with the ability to generate PBTs.
Materials and Methods
Tissue Collection and Grading. PBT and nontumor human brain
specimens from patients undergoing neocortical resections for
intractable epilepsy were obtained within 30 min of surgical
resection in accordance with protocols approved by institutional
review boards at University of California Los Angeles Medical
Center and the California Institute of Technology. The epilepsy
surgery tissue was taken from the lateral ventricular surface and
immediately adjacent tissues. Tumors were graded at the Uni-
versity of California Los Angeles Medical Center by the attend-
ing neuropathologist in accordance with World Health Organi-
zation (WHO) established guidelines (22).
Neurosphere Culture. Tumor and neurosphere cultures were per-
formed as according to Svendsen et al. (23) with some modifi-
cations. A detailed protocol is found in Supporting Methods,
which is published as supporting information on the PNAS web
site. Briefly, tissue was washed, minced, digested with trypsin,
dissociated, and passed through a series of cell strainers. Cells
were seeded in growth medium supplemented with basic fibro-
blast growth factor (20 ngml), epidermal growth factor (20
ngml), and leukemia inhibitory factor (20 ngml) at a density
of 100,000 cells per ml. Clonal cultures were plated at a density
of 1,000 cells per ml in mouse neurosphere-conditioned medium
(24), a density that has been demonstrated to produce almost
entirely clonal neurospheres (25).
Abbreviations: PBTs, pediatric brain tumors; NSCs, neural stem cells; GFAP, glial fibrillary
acidic protein; DAPI, 4,6-diamidino-2-phenylindole.
To whom correspondence should be addressed at: Room 1126 CIMI, 700 Westwood Plaza,
Los Angeles, CA 90095. E-mail: hkornblum@mednet.ucla.edu.
© 2003 by The National Academy of Sciences of the USA
15178–15183  PNAS  December 9, 2003  vol. 100  no. 25 www.pnas.orgcgidoi10.1073pnas.2036535100
Immunocytochemistry of Neurospheres. Immunocytochemistry of
neurosphere cultures was performed as described (24). Differ-
entiation of early passage (4 weeks) spheres was induced by
plating onto coverslips precoated with poly-L-lysine (Sigma) in
Neurobasal medium (GIBCO–Invitrogen) supplemented with
B-27 and in the absence of added basic fibroblast growth factor
or epidermal growth factor. After 7 days, the neurospheres were
fixed in 4% paraformaldehyde and immunostained with rabbit
anti-nestin (1:200; Chemicon) or rabbit anti-musashi (1:200;
Chemicon) for neural stem and progenitor cells, mouse anti-
TuJ1 (1:500; Berkeley Antibodies) or anti-Hu (1:300; Molecular
Probes) for neurons, rabbit anti-glial fibrillary acidic protein
(GFAP; 1:500; DAKO) for astrocytes, and anti-O4 (1:40;
Chemicon) for oligodendrocytes, followed by Alexa fluoro-
phore-conjugated secondary antibodies (1:2,000; Molecular
Probes). In some cases, nuclei were counterstained with 4,6-
diamidino-2-phenylindole (DAPI).
Statistical Analysis. Statistical analysis of cell counts was per-
formed as described in Supporting Methods.
Immunohistochemistry of Whole Tumor Sections. Formalin-fixed,
paraffin-embedded tissue specimens from tumors BT1, -2, -3,
and -5 were sectioned at 8m, mounted on Superfrost Plus slides
(Fisher), deparaffinized, and processed for antigen retrieval by
microwave heating as described (26).
BrdUrd-Labeling of Neurospheres. Neurospheres were cultured in
proliferative medium containing 2 M BrdUrd (5-bromo-2-
deoxyuridine) for 14 h. The cells were fixed in 4% phosphate-
buffered paraformaldehyde solution. Staining with anti-BrdUrd
antibody (Becton Dickinson) was performed according to the
supplier’s suggestions, and fluorescent secondary antibody was
used.
Semiquantitative RT-PCR. Semiquantitative RT-PCR was per-
formed with glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) as an internal standard as described in Supporting
Methods.
Transplantation of Neurosphere Cells into Neonatal Rat Brain. Trans-
plantation of 50,000 cells into the neostriata of neonatal rats was
performed according to the methods of Uchida et al. (27) with
modifications as described in Supporting Methods.
Immunohistochemical Analysis of Transplanted Rat Brain. Four weeks
after transplantation, tissue was prepared for immunocytochem-
ical analysis as described in Supporting Methods and stained with
antibodies directed against human nuclei, neurons, astrocytes,
and Ki-67.
Results
Twenty-two PBTs were used in the current studies: 10 gliomas
(including 2 glioblastomas), 6 medulloblastomas, 5 primitive
neuroectodermal tumors, and 1 ependymoma. For detailed
analysis of cell fate and gene expression, we studied a subgroup
of 6 tumors from 5 pediatric patients, aged 5 months to 6 years
[designated tumors 1–5 (BT1–BT5); Table 1]. These were a
midline anaplastic astrocytoma (World Health Organization
grade III astrocytic tumor; BT1), two cerebellar medulloblasto-
mas (BT2 and BT3), one glioblastoma multiforme (World
Health Organization grade IV astrocytic tumor; BT4), and one
desmoplastic medulloblastoma (BT5), distinguished from me-
dulloblastoma by marked neuronal differentiation (22).
Brain Tumor Cells Have the Ability to Form Neurospheres. Dissociated
tumor cells were assayed for their ability to form neurospheres by
using the same methods as described previously for human NSCs
(23, 27). All 22 primary brain tumors studied produced proliferating
neurospheres. Large numbers of small spheres 4–10 cells in
diameter were observed in culture flasks between 3 and 7 days after
seeding the cells at 100,000 per ml. Within 2 weeks, most spheres
had increased their diameters 5- to 10-fold (Fig. 1A). Cells from
a local recurrence of one tumor (BT4, glioblastoma multiforme)
Table 1. Tumor and patient characteristics
Tumor
Patient
age Diagnosis Site of tumor
BT1 5 years Anaplastic astrocytoma Midline
hypothalamus
BT2 5 months Medulloblastoma Cerebellum
BT3 6 years Medulloblastoma Cerebellum
BT4 6 years Glioblastoma multiforme Temporal lobe
BT5 15 months Desmoplastic medulloblastoma Cerebellum
Fig. 1. Tumor-derived progenitors form neurospheres in culture that give rise to both neuronal and glial cells. Neurospheres from one tumor, BT1, were cultured
at medium (A–D) and clonal (E–H) densities. (A) A typical primary neurosphere. (B and C) Undifferentiated primary neurospheres expressed high levels of nestin
protein (B, green) and low levels of -III-tubulin (C, red) and GFAP (C, green). (D) Expression of-III-tubulin and GFAP, after 7 days of differentiation on substrate.
(E) Nestin expression in undifferentiated clonal neurosphere cells. (F) Musashi-1 (green) expression in undifferentiated clonal neurospheres. (G)-III-tubulin (red)
and GFAP (green) expression in a differentiated clonal neurosphere. Some cells (arrows) expressed both markers. (H) Hu (green) expression in a differentiated
neurosphere. Some nuclei were counterstained with DAPI (F and H, blue). (Scale bar in H  30 m in A, G, and H, 60 m in B–F.)
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also gave rise to spheres in culture. Neurospheres could be passaged
multiple times by mechanical dissociation of large spheres and
reseeding in fresh proliferative medium every 2–3 weeks and could
be maintained for 16 weeks or more.
We next asked whether tumor-derived progenitors maintained
the differentiative capacity of NSCs by examining the types of
molecular markers expressed by neurospheres grown under both
proliferative and differentiating conditions with immunocyto-
chemistry. For most tumors, undifferentiated tumor spheres in
proliferation medium contained many cells expressing the neural
progenitor marker nestin (28) (Fig. 1B; except BT3) and rela-
tively few cells expressing the neuronal marker -III-tubulin
andor the astrocytic marker GFAP (Fig. 1C). These charac-
teristics persisted even in long-term cultures (10–16 weeks).
Under differentiating conditions, cell division in the spheres
slowed dramatically and attached cells migrated on the substrate.
Immunocytochemstry revealed an increase in the proportion of
cells expressing -III-tubulin andor GFAP. Differentiated neu-
rospheres produced numerous cells resembling neurons and
astrocytes, with many cells extending processes on the substrate
(Fig. 1D).
Tumor-Derived Progenitors Can Be Serially Recloned. Self-renewal
and multipotency are critical features of neural and other stem
cells. We next tested whether individual cells derived from these
neurospheres had the ability to form new neurospheres that
subsequently differentiated into multiple cell types. Primary
neurospheres were dissociated into single-cell suspensions and
reseeded at clonal density in proliferative medium. After 1 day,
only individual cells and no clusters could be observed, verifying
their clonal origin. In all cases, clonally derived neurospheres
were visible within 2–4 weeks after reseeding, suggesting that
neurospheres contain individual stem-like cells with the ability
to self-renew and form neurosphere colonies.
Immunocytochemistry was used to compare the molecular
markers expressed by clonal neurospheres grown under prolif-
eration and differentiation conditions. Undifferentiated clonal
spheres from four of five tumors expressed nestin in a large
percentage of their cells (45%) with little variability between
clones (Figs. 1E and 2 A, B, D, and E). However, nestin protein
expression was undetectable in BT3, a medulloblastoma (Fig.
2C). In addition, tumor-derived spheres expressed musashi-1,
another marker of NSCs (Fig. 1F) (29). After transfer to
differentiating conditions for 7 days, the proportion of nestin-
expressing cells declined in clonal spheres derived from three of
the four tumors (Fig. 2 A, B, and D); it remained unchanged only
in BT5, a desmoplastic medulloblastoma (Fig. 2E).
We quantitatively compared the cell types produced by spheres
before and after differentiation by using cell type-specific markers.
Clonal neurospheres gave rise to cells with neuronal and glial
properties. Under differentiation conditions, the majority of clones
from each tumor gave rise to cells resembling both neurons and glia,
with many cells per sphere expressing -III-tubulin andor GFAP
(Fig. 1G). The percentage of -III-tubulin cells in clonal spheres
increased significantly after transfer to differentiation conditions in
all tumors except BT5, a desmoplastic medulloblastoma (Fig. 2
Left). The percentage of GFAP cells in clonal spheres increased
significantly after differentiation in all tumors except BT4, a glio-
blastoma multiforme (Fig. 2 Left). Differentiated clonal spheres
expressed the neuronal HuCD antigen in proportions similar to
their expression of -III-tubulin (Fig. 1H). In contrast, the oligo-
dendrocyte marker O4 could not be detected by immunocytochem-
istry in clonal or high-density neurospheres. These results show that
tumors contain progenitor cells that are multipotent, giving rise to
cells with neuronal and glial characteristics.
Despite their all being multipotent, the percentage of differ-
entiated cell types produced varied considerably from one tumor
to another (Fig. 2 Right). BT5 produced only neurospheres that
differentiated into both neurons and glia. The remaining tumors
gave rise to a mixture of clones, some of which formed multiple
cell types and others that formed only neuron-like cells.
Properties of Clonally Derived Spheres Recapitulate Characteristics of
the Parental Tumors. To determine whether the above findings
recapitulate the properties of the parental tumors, we examined
nestin, GFAP, and TuJ1 staining of four tumors (Fig. 3). The
staining patterns were broadly similar to those observed in
tumor-derived spheres. For example, BT1 expressed high levels
of nestin within the tumor (Fig. 3A) as well as in neurospheres.
Fig. 2. Neurospheres derived from multiple types of tumors give rise to cells
expressing neuronal and glial markers in various proportions. (Left) Average
count of cells expressing nestin, TuJ1 alone, GFAP alone, or both markers in
clonal neurospheres (NS) from BT1–5 (A–E) before (white) and after (black)
differentiation. (Right) Fates of clonal neurospheres (NS) after differentiation.
Markers used are TuJ1 for neurons (N) and GFAP for astrocytes (A).
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Many cells in this same tumor expressed either TuJ1or or GFAP
(Fig. 3E). BT2 (Fig. 3 B and F) also expressed all three markers
but at lower levels than BT1, both in the parent tumor and in the
neurospheres. BT3 had little nestin staining in the tumor (al-
though nestin is obvious in the adjacent normal brain; Fig. 3C);
this low level of nestin parallels that observed in the neuro-
spheres (compare Figs. 2C and 3C). With respect to TuJ1 and
GFAP (Fig. 3G), BT3 had strong reactivity for both, as did the
neurospheres (Fig. 2C). BT5 showed good correlation between
the amount of TuJ1 and GFAP staining in both the tumors (Fig.
3H) and neurospheres (Fig. 2E); in contrast, nestin expression
did correlate well between tumor and neurosphere in this one
particular case (Figs. 3D and 2E). Taken together, these data
indicate that the tumor-derived spheres, even after weeks in
culture, differentiate similarly to the original tumors from which
they were derived in the majority of cases.
Tumor-Derived Neurospheres Express NSC-Related Genes. We used
semiquantitative RT-PCR analysis to determine whether neu-
rospheres cultured from PBTs expressed multiple genes en-
riched in neural and other stem cells, and to compare expression
among proliferating and differentiating tumor progenitors as
well as the parent tumor. Primers were designed for the following
human genes: CD133, a cell surface protein expressed on all fetal
human NSCs (27); musashi-1 (msi1) (30); Sox2, an early tran-
scription factor expressed in NSCs and the developing neural
tube (31, 32); and bmi-1, a Polycomb Group gene required for
self-renewal and proliferation of normal and leukemic hemato-
poietic stem cells (33, 34). We also examined the expression of
two genes that we have identified from mouse neural progenitors
by a subtractive microarray screening approach: melk, maternal
embryonic leucine zipper kinase and PSP, phosphoserine phos-
phatase (24, 35, 36). Both of these genes are highly and selec-
tively expressed in murine central nervous system germinal zones
and are present in both neural progenitors.
All tumors as well as cells derived from the ventricular zone of
normal brain had detectable gene expression of CD133, Sox2, melk,
PSP, and bmi-1 (Table 2). Those genes expressed in both tumor-
derived and normal neurospheres were also expressed in their
parental tissues, suggesting that gene expression observed in neu-
rospheres is not an artifact of cell culture. Sox2, melk, and bmi-1
were expressed in all whole tumor, normal brain, and undifferen-
tiated neurosphere samples. Expression of some genes, most no-
ticeably PSP, was reduced or lost in spheres, as compared with
whole tumor or ventricular zone-containing tissue. This finding
suggests either that uncultured tissues expressed these genes at
higher levels than their neurosphere-initiating cells and their prog-
eny or that these genes were down-regulated as a consequence of
cell culture. Neurospheres from BT1 and BT4, both glial tumors of
different pathological grades, expressed nearly all stem cell-related
genes, but BT3 and BT5, both medulloblastomas, had significantly
lower or absent detectable expression of those genes, indicating that
cells in glial tumors might have a closer molecular relation to NSCs.
msi1 expression was variable but clearly present in spheres derived
from two of the five tumors. In 11 instances, expression of specific
genes in the tumor-derived spheres was reduced after growth factor
withdrawal, consistent with our prediction that tumor-derived
progenitors would produce differentiated cells at the expense of
multipotent progenitor cells.
All tumor-derived neurospheres maintained high bmi-1 ex-
pression both under proliferative and after differentiative con-
ditions. In contrast, normal neurospheres had significantly less
bmi-1 expression, which further declined after differentiation.
Tumor-Derived Neurospheres Incorporate into Rat Brain. To test
whether tumor-derived progenitors possess the ability to migrate
and differentiate after transplantation into rodent brain, similar to
normal human progenitors (27, 37), 50,000 dissociated cells from
neurospheres derived from BT4 at passage 4 were injected into the
neostriata of neonatal rats. The data shown in Fig. 5, which is
published as supporting information on the PNAS web site, dem-
onstrate that the transplanted cells incorporate into the brain, have
the characteristics of migrating neurons (38), differentiate into
neuronal and glial elements, and continue to divide as demon-
strated by expression of Ki-67, a marker of cycling cells (39).
Tumor-Derived Neurospheres Are Different from Normal Neuro-
spheres. We compared the properties of tumor-derived neuro-
spheres with those of normal neurospheres cultured from the brain
tissue of pediatric epilepsy surgery patients. The data suggest that
tumor-derived progenitors are not derived from contaminating
normal NSCs. Tumor-derived neurospheres could be maintained
for at least 4 months with no obvious change in their proliferative
properties, whereas normal neurospheres grown under identical
conditions persisted no longer than 1 month in culture. Tumor-
derived spheres demonstrated unusual proliferation even in appar-
ently differentiated cells. We observed cells that expressed both
-III-tubulin and Ki-67, suggesting that cells with the appearance of
differentiated neurons were dividing (BT4; Fig. 4A). Moreover,
50% of -III-tubulin cells derived from this tumor incorporated
BrdUrd after a 14-h pulse, indicating that a significant proportion
of tumor-derived neurons divided over a brief time (Fig. 4B).
Another distinctive feature of tumor-derived progenitors was
that they gave rise not only to neurons and glia but also to cells
Fig. 3. Immunohistochemical characteristics of original tumor samples. Paraffin-embedded sections were labeled with antibodies to nestin (green; A–D) or TuJ1
(red; E–H) to recognize neurons or GFAP (green; E–H) to recognize glia. Area denoted by asterisk in C and F delineates normal brain tissue adjacent to the tumor.
(Scale bar in H  60 m in A–H.)
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that expressed both -III-tubulin and GFAP (Fig. 2). Such
dual-fate cells were common and represented a significant
fraction of the population. -III-tubulin GFAP cells were
often larger than other cells in the same sphere (Fig. 1G, arrows).
In two tumors, BT1 and BT5, the percentage of -III-tubulin
GFAP cells exceeded the percentage of cells expressing -III-
tubulin or GFAP alone (Fig. 2). Previous studies have reported
similar abnormal cells derived from adult brain tumors (40).
Discussion
In the present study, we asked whether pediatric brain tumors
contain neural stem-like cells that may be responsible for their
formation. Our results show that tumor-derived cells have the
ability to form neurospheres and can be propagated for prolonged
times in culture. This property is a general property of all of the 22
tumors examined in this study. We demonstrate that tumor-derived
progenitors and NSCs express many of the same genes and proteins,
and they share some common characteristics, including self-renewal
and multipotency. However, the types of progeny arising from
neurospheres vary from tumor to tumor and, to some extent,
recapitulate the properties of their tumor of origin.
Among the characteristics in common between tumor-derived
spheres and normal neural stem cells is the expression of specific
genes, including CD133, musashi-1, Sox2, melk, PSP, bmi-1, and
nestin. Only one of the tumors we studied, a medulloblastoma
(BT3), failed to express nestin in most cells in undifferentiated
clonal neurospheres. Interestingly, BT3 was the least neural stem
cell-like of all of the tumors we tested, giving rise to a low
percentage of multipotent neurospheres that lacked expression
of most known stem cell genes. Sox2, a gene known to play a role
in maintenance of the neural progenitor state (41) was expressed
by all tumors and neurospheres tested. In addition, tumor-
derived spheres express other markers that are specifically
enriched in NSCs, such as maternal embryonic leucine zipper
kinase and phosphoserine phosphatase (35, 36).
Although tumor-derived progenitors have many similarities to
NSCs and to each other, it is important to note that differences
exist between them and NSCs as well as between tumor-derived
progenitors from different tumors. For example, unlike normal
neurospheres, cancer-derived neurospheres undergo aberrant
proliferation and differentiation. Clonally derived spheres from
an individual tumor generally gave rise to similar percentages of
neuron- and glial-like cells, suggesting that each tumor contained
a fundamental type of stem cell. However, the degree of
differentiation and types of cells produced differed from tumor
to tumor, possibly reflecting a fundamental difference in the
progenitor cells of different tumors.
One finding of our study is that the tumor-derived neuro-
spheres tend to differentiate into an array of progeny with the
same general profile as the parental tumor. Immunohistochem-
ical analysis of the original tumor revealed striking similarities
with the corresponding neurospheres, suggesting that the pres-
ence of diverse cell types in the tumors is not simply a result of
the presence of ‘‘host’’ cells within the tumor mass, but rather is
a property of the tumor itself.
Our finding that PBTs contain neural stem-like cells is con-
sistent with the hypothesis that at least some PBTs are derived
from transformed NSCs in the central nervous system. It has
previously been hypothesized that medulloblastomas and prim-
Table 2. Gene expression analysis
Gene BT1 BT2 BT3 BT4 BT5 Normal
Whole tumors
CD133 ND     
msi1 ND     
Sox2 ND ND    
melk ND     
PSP ND     
bmi-1 ND ND ND   
Undifferentiated neurospheres
CD133      
msi1      
Sox2   ND   
melk      
PSP      
bmi-1   ND  ND 
Differentiated neurospheres
CD133      
msi1   ND   
Sox2      
melk      
PSP      
Bmi-1   ND   
Semiquantitative RT-PCR of pediatric brain tumors (BT1–5) and normal human brain was used to analyze
expression of stem cell markers. ND, not determined;, no signal;, minor signal;, weak signal;, moderate
signal; , strong signal.
Fig. 4. Tumor-derived neurospheres give rise to neurons that proliferate
aberrantly. (A) Clonal neurosphere derived from the BT4 tumor, double-
labeled for -III-tubulin (red) and Ki-67 (green). Nuclei were counterstained
with DAPI (blue). (B) Double-label for BrdUrd (green), visualized after a 14-h
pulse and TuJ1 (red). (Scale bar in B  15 m in A and B.)
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itive neuroectodermal tumors (PNETs) are derived from mul-
tipotent progenitor cells (8). Our data suggest that these tumors
are somewhat similar to NSCs but more strongly suggest that
pediatric astrocytomas and high-grade gliomas are derived from
either NSCs or progenitor cells. Previous studies have demon-
strated that adult high-grade gliomas can form multiple differ-
entiated cell types (42), and that some cells can form neuro-
spheres with multiple differentiated cell types (40). It is unknown
whether the originating cells of PNETs, medulloblastomas and
gliomas, may be the same type of cell, such as a NSC, but
resulting from different transformation events, or whether the
glial tumors arise from a cell at a later stage of differentiation.
In the latter case, a tumor may arise from a glial cell that is caused
to dedifferentiate by a transforming event or from a more
gliogenic, but still multipotent, stem cell. In support of the latter
hypothesis is the strong evidence to indicate that there is a
lineage of cells that progresses from primitive cells within the
neural tube to radial glia to GFAP-expressing ‘‘astrocytes’’ that
all retain the fundamental properties of NSCs: self-renewal and
multipotency (11, 43). Additionally, it is possible that medullo-
blastomas arise not from a true NSC, but rather from a different
type of progenitor, such as a cerebellar granule cell. In any of the
alternatives presented above, the ultimate result would still be
that the tumors themselves contain multipotent self-renewing
stem-like cells.
The mechanism whereby normal NSCs may become malignant
is not clear. Our data demonstrate that normal and tumor-
derived spheres express bmi-1, with sphere expression being
maintained even after withdrawal of mitogen, in contrast to what
was observed in normal neural progenitors. This gene has been
demonstrated to be important for self-renewal of both leukemic
and normal hematopoietic stem cells (33, 34). It is possible that
the high level and persistent expression of bmi-1 in tumor cells
indicates a greater capacity for self-renewing divisions.
Our data raise the possibility, but do not prove, that tumor-
derived progenitors are cancer stem cells for PBTs. While we
have shown that at least some tumor-derived progenitors, like
normal NSCs, are able to migrate, proliferate, and differentiate
when transplanted into developing rat brains, it is not yet known
whether the tumor-derived progenitors also have the ability to
form tumors in an animal model.
Knowledge of the developmental origin of PBTs has impor-
tant implications for therapy. Our results demonstrate that these
tumors contain cells that are multipotent and self-renewing and
are consistent with the hypothesis that these tumors are derived
from progenitor cells with stem-cell like properties. These
observations suggest that therapies for treating PBTs should
include methods for targeting and elimination of the stem cell
population.
Note Added in Proof. After the final revision of this manuscript was
submitted, another paper also demonstrating the presence of multipo-
tent progenitors in brain tumors was published (44).
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